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Background: International surgeon series and registry data have demonstrated positive outcomes and long-term sur-
vival of the Birmingham Hip Resurfacing (BHR) implant. We report the 5 to 10-year results from a single center in the U.S.
Methods: Three hundred and fourteen patients (360 hips) underwent surface replacement arthroplasty with use of the
BHR implant and consented to study participation. Patient-reported outcomes and complication and revision data were
collected at a minimum of 5 years of follow-up for 93% (324 of 350) of the hips in surviving patients. A matched-cohort
analysis was used to compare clinical outcomes between use of the BHR and total hip arthroplasty.
Results: Mean modiﬁed Harris hip score (mHHS) and University of California, Los Angeles (UCLA) scores signiﬁcantly
improved postoperatively, to 89.9 and 8.0, respectively (p < 0.001). The Kaplan-Meier estimated rate of survival for all-
cause revision was 97.2% (95% conﬁdence interval [CI], 94.7% to 98.5%) and 93.8% (95% CI, 88.8% to 96.7%) at 5 and
10 years, respectively. In a subgroup analysis of patients ﬁtting our current BHR inclusion criteria (males <60 years of
age with a diagnosis of osteoarthritis and anatomy conducive to a femoral head component of ‡48 mm), survival free of
aseptic revision was 99.5% (95% CI, 96.6% to 99.9%) at 5 years and 98.2% (95% CI, 94.4% to 99.4%) at 10 years.
Fourteen patients (4.3% of all hips) required revision. Postoperative UCLA scores were signiﬁcantly greater for BHR
compared with total hip arthroplasty (mean score of 8.0 ± 2.0 versus 7.6 ± 1.8; p = 0.040) in a matched-cohort
analysis, with patients matched according to preoperative UCLA score, diagnosis, age, sex, and body mass index.
Among matched patients who were highly active preoperatively (UCLA score of 9 to 10), BHR provided a smaller median
decrease in the postoperative UCLA score (0.0 versus 1.0; p < 0.001), which was clinically important according to the
minimal clinically important difference (MCID, 0.92). Furthermore, BHR provided a greater likelihood of remaining highly
active compared with total hip arthroplasty (61% compared with 20%; p < 0.001).
Conclusions: BHR demonstrated excellent survivorship and clinical outcomes at 5 to 10 years in selected patients. As
compared with total hip arthroplasty, the use of the BHR may provide highly active patients with clinically important
advantages in postoperative activity as well as a greater likelihood of remaining highly active. Continued follow-up is
necessary to validate long-term BHR outcomes.
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etal-on-metal (MoM) surface replacement arthro-
plasty has demonstrated promise as a treatment for
osteoarthritis of the hip, especially in young, active
males1. Poor outcomes and frequent adverse local tissue reac-
tions (ALTRs) associated with MoM total hip arthroplasty,
however, have led to generalized caution regarding the use of
MoM devices. Furthermore, the 2010 recall of the ASR implant
(DePuy) and a 2008 study by Pandit et al.2, reporting pseudo-
tumors in 17 female patients (20 hips) who underwent surface
replacement arthroplasty, have contributed to diminished uti-
lization of MoM surface replacement arthroplasty systems.
Results of MoM surface replacement arthroplasty, how-
ever, are highly dependent on the speciﬁc device being utilized as
well as the demographics of the patient population being treated.
In 2016, the Australian Orthopaedic Association National Joint
Replacement Registry reported favorable 15-year revision rates
for surface replacement arthroplasty, but only 3 of the 11 surface
replacement arthroplasty device combinations under investiga-
tion demonstrated implant survival similar to that of total hip
arthroplasty: the ADEPT (MatOrtho), theMITCHTRH (Stryker),
and the Birmingham Hip Resurfacing (BHR; Smith & Nephew)
devices3. Although the BHR implant has been available in the U.K.
for 20 years, it only received U.S. Food and Drug Administration
(FDA) approval in 2006, and it remains the only surface replace-
ment arthroplasty implant available and approved for use in the
U.S. Furthermore, it is only 1 of 2 surface replacement arthroplasty
implants to have received a 10A rating or greater from the Or-
thopaedicDevice EvaluationPanel in theU.K., and the only surface
replacement arthroplasty implant to receive the maximum possi-
ble rating of 10A*4.
Surface replacement arthroplasty has potential advan-
tages, including the restoration of native hip biomechanics,
decreased incidence of instability, decreased morbidity with
revision surgery, and improved function with high-demand
activities5-9. However, because surface replacement arthroplasty
is a more technically demanding procedure with a greater cost
compared with total hip arthroplasty10, it must demonstrate
similar complication rates and survivorship, as well as potential
clinical advantages, in order to justify its use.
While BHR data from foreign studies and registries have
demonstrated survivorship equal to that of total hip arthro-
plasty in select patient groups8,11-15, no U.S. study that we are
aware of has reported on survivorship beyond the mid-term.
The primary aim of the current study was to report BHR
survivorship and outcomes at 5 to 10 years. A secondary aim of
this study was to compare the clinical outcomes of matched
BHR and total hip arthroplasty cohorts in order to determine if
BHR use confers relative advantages among highly active patients.
Materials and Methods
Study Cohort
Our study cohort represents a consecutive series of 314patients (360 hips) who received BHR implants between
June 2006 and December 2011 and consented to study par-
ticipation; the procedures were performed by 3 surgeons
(R.L.B., J.C.C., and R.M.N.). Seven patients (10 hips) died
before reaching the minimum 5-year follow-up, leaving 307
patients (350 hips) for inclusion in the study. Minimum 5-
year follow-up data were collected for 93% (324) of the hips
(283 patients), while 7% (26) of the hips (24 patients) were
lost to follow-up (Fig. 1). Patient characteristics are shown in
Table I.
Indications
At our institution and others, the use of BHR is currently
limited to active males <60 years of age with a primary
diagnosis of osteoarthritis and anatomy conducive to a
femoral head component of ‡48 mm, on the basis of FDA
Fig. 1
Patient ﬂow diagram. FU = follow-up.
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recommendations and implant availability as well as of prior
studies describing optimal BHR utilization3,16,17. Because this
study includes our institution’s initial experience with the use
of BHR prior to the implementation of these criteria, 36% of
our included patients had at least 1 factor that would have
excluded them on the basis of our current criteria. Therefore,
we investigated outcomes for the general cohort as well as for
the subgroup representing the current inclusion criteria, al-
lowing us to determine the expected performance of the BHR
implant in today’s population.
Surgical Procedure
An extensile posterior approach, as described by Daniel et al.,
was used in all cases12. As per FDA guidelines, routine metal ion
levels and advanced imaging were not assessed for asymp-
tomatic patients18. Surgical data are shown in Table II.
Clinical and Patient-Reported Outcomes
Preoperative patient demographic data, including age, sex,
and body mass index (BMI); disease diagnosis; and Ameri-
can Society of Anesthesiologists (ASA) score (Table I) as well
as patient-reported outcomes data, such as modiﬁed Harris
hip score (mHHS) and University of California, Los Angeles
(UCLA) activity score, were obtained from an institutional
registry.
Postoperatively, patient-reported outcomes data includ-
ing mHHS, UCLA score, satisfaction level (1 = unsatisﬁed, 2 =
somewhat satisﬁed, 3 = satisﬁed, 4 = very satisﬁed, and 5 =
extremely satisﬁed), and a binary satisfaction response (yes or
no) for all patients with a minimum of 5 years of follow-up
were collected from our institutional registry. Patients lacking
5-year follow-up data were contacted via telephone to com-
plete patient-reported outcomes surveys and answer questions
regarding failure of the procedure and complications. Data are
presented as of the most recent follow-up or at the time of
failure. All failed cases, with “failure” deﬁned as the need for
revision hip surgery, as well as the time to failure and reasons
for failure, were recorded.
Radiographic Outcomes
Minimum 5-year radiographic follow-up was available for 280
(86.4%) of the hips. Two of the authors (M.C.F. and M.D.H.)
independently assessed anteroposterior and cross-table lateral
radiographs for radiolucencies, component loosening, femoral-
neck narrowing, and heterotopic ossiﬁcation as well as ace-
tabular inclination and anteversion and femoral neck-shaft
angle. Acetabular and femoral component radiolucencies were
assessed in accordance with previously described methods19,20
TABLE II Surgical Data*
Values
Extensile posterior approach 324 (100)
Implant femoral head size (mm) 50.1 ± 3.3 (42-58)
Implant acetabular shell size (mm) 56.8 ± 3.1 (48-66)
Implant anteversion () 23.0 ± 7.2 (25-52)
Implant inclination () 42.0 ± 5.2 (25-60)
Implant femoral neck-shaft angle () 138.9 ± 6.1 (112-160)
*The values for extensile posterior approach are given as the
number of hips, with the percentage in parentheses. All other
values are given as the mean and standard deviation, with the
range in parentheses.
Fig. 2
Assessment of radiolucency surrounding the femoral component. Num-
bers1 to3 represent the zonesof the femoral stem,whileRomannumerals
I to IV represent the Charnley zones19-21.
TABLE I Patient Characteristics*
Values




BMI (kg/m2) 27.0 ± 3.5 (17.4-40.0)
ASA score 1.89 ± 0.5 (1-4)
Osteoarthritis 304 (93.8)
Rheumatoid arthritis 1 (0.3)
Head destruction 3 (0.9)
Osteonecrosis 10 (3.1)
Posttraumatic arthritis 6 (1.9)
*The values for age, BMI, and ASA score are given as the mean
and standard deviation, with the range in parentheses. All other
values are given as the number of hips (n = 324), with the
percentage in parentheses.
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(Fig. 2). Femoral-neck narrowing was assessed as described
by Hing et al., with narrowing deﬁned as a reduction in the
femoral neck of >10%21. The average value for each measure
was utilized in the ﬁnal analysis.
Matched Total Hip Arthroplasty Cohort
Postoperative BHR outcomes were then compared with out-
comes following total hip arthroplasty obtained from our
institutional outcomes database. The use of BHR is reserved for
Fig. 3-A Fig. 3-B
Fig. 3-A Kaplan-Meier estimated survival for all-cause revision. The rate of survival free from revision for any cause (n=324, 100%of the cohort) was97.2%
(95% conﬁdence interval [CI], 94.7% to 98.5%) at 5 years and 93.8% (95%CI, 88.8% to 96.7%) at 10 years. The shaded area represents the 95%CI. BHR=
BirminghamHip Resurfacing.Fig. 3-B Kaplan-Meier estimated survival for aseptic revision. The rate of survival free from aseptic revision (n= 321, 99.1%)
was 98.1% (95% CI, 95.9% to 99.2%) at 5 years and 94.7% (95% CI, 89.6% to 97.4%) at 10 years. The shaded area represents the 95% CI. BHR =
Birmingham Hip Resurfacing.
Fig. 4-A Fig. 4-B
Fig. 4-A Kaplan-Meier estimated survival for all-cause revision among patientsmeeting the current inclusion and exclusion (I/E) criteria compared with the
rest of the cohort. The current inclusion criteria aremale patients<60 years of agewith a preoperative diagnosis of osteoarthritis and anatomyconducive to
a femoral head component of‡48mm. The rate of survival free from revision for any cause for this subgroup (n=208, 64.2%)was98.1% (95%CI, 95.0% to
99.3%)at5 yearsand96.8% (95%CI,92.9% to98.6%) at10years comparedwith95.7% (95%CI,90.0% to98.2%)at5 yearsand90.3% (95%CI,80.1% to95.4%)
at 10 years for the remaining cohort (n= 116, 35.8%). The shaded areas represent the 95%CI. BHR=BirminghamHip Resurfacing.Fig. 4-B Kaplan-Meier
estimated survival for aseptic revision among patients meeting the current inclusion and exclusion (I/E) criteria compared with the rest of the cohort. The
current inclusion criteria are male patients <60 years of age with a preoperative diagnosis of osteoarthritis and anatomy conducive to a femoral head
component of ‡48mm. The estimated rate of survival free fromaseptic revision for this subgroup (n=205, 63.3%)was99.5% (95%CI, 96.6% to 99.9%) at
5 years and98.2% (95%CI, 94.4% to99.4%) at 10 years comparedwith95.7% (95%CI, 90.0% to98.2%) at 5 years and90.3% (95%CI, 80.1% to95.4%) at
10 years for the remaining cohort (n = 119, 36.7%). The shaded areas represent the 95% CI. BHR = Birmingham Hip Resurfacing.
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highly active patients who often speciﬁcally request it in order
to remain competitive in high-demand activities, precluding an
accurate comparison of BHR results and outcomes of total hip
arthroplasty in the general population. We therefore performed
a 1:1 matched-cohort analysis based on the following param-
eters: (1) a preoperative diagnosis of osteoarthritis, (2) patient
age of <60 years, (3) male sex, (4) BMI within 3 kg/m2, and (5)
a preoperative UCLA score within 1. In order to determine
whether highly active patients received an additional beneﬁt
from BHR compared with total hip arthroplasty, we performed
a subgroup analysis comparing median postoperative UCLA
scores between BHR and total hip arthroplasty patients who
had preoperative UCLA scores of 9 to 10 (patients capable of
participating in impact sports22). On the basis of the ﬁndings of
SooHoo et al. establishing the minimal clinically important
difference (MCID) for the UCLA score, we set the threshold for
clinical importance at 0.9223. Finally, we compared the post-
operative likelihood of remaining highly active between BHR
patients and total hip arthroplasty patients who were highly
active preoperatively.
Statistical Analysis
Statistical analyses were performed using SAS (version 9.4;
SAS Institute). Preoperative and postoperative mHHS and
UCLA scores were compared using a paired t test. Kaplan-
Meier analysis was used to estimate the 5 and 10-year rates of
survival free from revision for any cause and from aseptic
revision for the full cohort as well as for a cohort representing
the current BHR inclusion criteria (males of <60 years of age
with osteoarthritis and anatomy conducive to a femoral head
component of ‡48 mm). A log-rank test was used to compare
the current-indication subgroup with the greater cohort. Uni-
variable and multivariable Cox regression analyses were per-
formed in order to assess the relationship between demographic
risk factors and implant failure. BHR and total hip arthroplasty
patients were matched using the “greedy”matching algorithm in
the gmatch SAS macro24 and analyzed using a paired t test
(UCLA and mHHS), Wilcoxon signed-rank test (satisfaction
ranking), andMcNemar test (satisfaction, yes or no). Differences
in the median change in UCLA score for total hip arthroplasty
and BHR subjects with preoperative scores of 9 to 10 were
compared using a median regression analysis.
Results
Survivorship Outcomes
The Kaplan-Meier estimated rate of survival free fromrevision for any cause (n = 324, 100% of the cohort) was
97.2% (95% conﬁdence interval [CI], 94.7% to 98.5%) at 5
years and 93.8% (95% CI, 88.8% to 96.7%) at 10 years (Fig.
3-A). The rate of survival free from aseptic revision (n =
321, 99.1%) was 98.1% (95% CI, 95.9% to 99.2%) at 5 years
and 94.7% (95% CI, 89.6% to 97.4%) at 10 years (Fig. 3-B).
In a subgroup analysis assessing implant survival among
patients representative of our current BHR inclusion cri-
teria (n = 208, 64.2%), the estimated rate of survival free
from revision for any cause for this subgroup was 98.1%
(95% CI, 95.0% to 99.3%) at 5 years and 96.8% (95% CI,
92.9% to 98.6%) at 10 years compared with 95.7% (95% CI,
90.0% to 98.2%) at 5 years and 90.3% (95% CI, 80.1% to
95.4%) at 10 years for the remaining cohort (n = 116,
TABLE III Associations Between Patient and Procedural Characteristics and Failure Using a Multivariate Cox Regression Analysis
Characteristic Successful Treatment* Failed Treatment* No. with Failure Hazard Ratio (95% CI) P Value
Age (yr) 52.1 ± 7.41 50.27 ± 9.11 — 0.97 (0.90-1.04) 0.370
Sex
Female (n = 44) — — 5 3.41 (1.14-10.20) 0.028†‡
Male (n = 280) — — 9
BMI (kg/m2) 27.13 ± 3.52 26.24 ± 4.37 — 0.93 (0.79-1.09) 0.379
Osteoarthritis (n = 297) — — 13 0.97 (0.13-7.42) 0.976
Acetabular inclination () 42.03 ± 5.19 41.29 ± 5.55 — 0.97 (0.87-1.07) 0.523
Acetabular anteversion () 23.04 ± 7.17 21.82 ± 8.83 — 0.96 (0.88-1.05) 0.364
Femoral head size
<48 mm (n = 91) — — 6 3.4 (1.18-9.80) 0.023†§
‡48 mm (n = 233) — — 8
*The values are given as the mean and standard deviation. †Signiﬁcant. ‡0.290 in the multivariate analysis. §0.138 in the multivariate analysis.
TABLE IV Perioperative Complications
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35.8%) (Fig. 4-A). The estimated rate of survival free from
aseptic revision in this subgroup (n = 205, 63.3%) was 99.5%
(95%CI, 96.6% to 99.9%) at 5 years and 98.2% (95% CI, 94.4%
to 99.4%) at 10 years compared with 95.7% (95% CI, 90.0% to
98.2%) at 5 years and 90.3% (95% CI, 80.1% to 95.4%) at 10
years for the remaining cohort (n = 119, 36.7%) (Fig. 4-B).
Patient sex and femoral component size were found to be
signiﬁcant predictors of implant failure. Female patients had a 3.4
(95% CI, 1.1 to 10.2)-times greater risk of all-cause failure com-
pared with male patients (p = 0.028). Femoral head sizes of
<48 mm had a 3.4 (95% CI, 1.2 to 9.8)-times greater risk of all-
cause failure compared with those of ‡48 mm (p = 0.023). The
effect of sex and femoral component size was not apparent in our
multivariate analysis (p > 0.05), but it is unclear whether this was
because of the correlation between sex and head size or the
underpowered nature of this analysis. The hazard ratios for various
patient and procedural characteristics are presented in Table III.
Patient-Reported Outcomes
The average mHHS (and standard deviation) was 54.3 ± 13.6
(range, 3.3 to 92.4) preoperatively, which improved to 89.9 ±
14.4 (range, 22.0 to 100.1) at the time of ﬁnal follow-up. This
average increase in the mHHS of 35.6 ± 18.4 (95% CI, 33.5 to
37.7) was signiﬁcant (p < 0.001). The average UCLA score





















(yr) Reason for Revision
High risk
M 41.4 Osteonecrosis 42 39 16 125 8.5 Femoral neck fracture
F 54.0 OA 42 36 20 156 8.2 Undiagnosed pain
F 34.4 OA 42 43 35 150 1.4 Fibrous ingrowth of cup
F 53.8 OA 46 40 40 141 5.0 ALTR and/or pseudotumor
F 52.7 OA 46 45 24 137 2.5 Persistent dislocation
F 52.2 OA 46 37 23 132 2.7 ALTR and/or pseudotumor
M 53.0 OA 48 36 30 140 5.6 Undiagnosed pain
M 42.1 OA 48 36 30 140 3.1 ALTR and/or pseudotumor
M 63.8 OA 50 37 22 137 4.8 ALTR and/or pseudotumor
M 65.2 OA 54 38 20 143 0.1 Fibrous ingrowth of cup
Low risk
M 52.3 OA 50 42 19 112 5.7 Femoral component
loosening
M 36.8 OA 50 55 7 146 3.7 Infection
M 46.2 OA 52 37 15 138 0.7 Infection
M 55.7 OA 54 44 11 134 4.8 Infection
*OA = osteoarthritis, and ALTR = adverse local tissue reaction.
TABLE VI Matched-Cohort Analysis
Variable BHR THA* Paired Difference P Value
No. of hips 159 159 — —
Median satisfaction level 5 5 0 (21, 1)† 0.99
Postop. mHHS‡ 91.6 ± 12.9 88.8 ± 16.0 2.9 ± 19.0 0.068
Postop. UCLA score‡ 8.0 ± 2.0 7.6 ± 1.8 0.4 ± 2.6 0.040§
Median decrease in UCLA score among highly active
patients (UCLA 9-10)
0.0 1.0 1.0 ± 0.45 <0.001§
Percentage of highly active patients (UCLA 9-10)
remaining highly active postop.
61% 20% — <0.001§
*THA = total hip arthroplasty. †The 95% conﬁdence interval is given in parentheses. ‡The values are given as the mean and standard deviation.
§Signiﬁcant.
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was 7.0 ± 2.5 (range, 2 to 10) preoperatively, improving to
8.0 ± 2.0 (range, 2 to 10) at the time of ﬁnal follow-up. This
average increase in the UCLA score of 1.0 ± 2.5 (95% CI, 0.7
to 1.3) was signiﬁcant (p < 0.001). The average patient-
satisfaction level was 4.5 ± 0.9 (range, 1 to 5) at the time of
ﬁnal follow-up.
Complications and Revisions
Perioperative complications are reported in Table IV. Fourteen
patients underwent BHR revision at an average of 4.1 years
(range, 0.1 to 8.5 years). Table V reports surgical and demo-
graphic details for each revision case.
Radiographic Results
Of the 280 radiographs available for interpretation, 4 hips had
an acetabular radiolucent line in Charnley zone I only; 1 hip, in
Charnley zone II; 1 hip, in Charnley zone III; 1 hip, in both
Charnley zones I and II; and 1 hip, in both Charnley zones II
and III. Six hips showed a femoral radiolucent line in stem zone
1 only; 3 hips, in stem zone 2; 1 hip, in stem zone 3; 2 hips, in
both stem zones 1 and 2; and 1 hip, in all 3 stem zones. Only
1 hip showed evidence of femoral notching. No patient had
continuous radiolucency or migration of either component.
Matched Cohort
A matched-cohort analysis demonstrated a signiﬁcant, 0.4 ± 2.6-
point advantage for BHR compared with total hip arthroplasty in
mean postoperative UCLA score (p = 0.040). The median satis-
faction level andmeanmHHS did not differ signiﬁcantly between
the 2 types of procedures. A subgroup analysis of the highly active
patients in the matched cohorts demonstrated that, among
patients with preoperative UCLA scores of 9 to 10, a signiﬁcantly
smaller median decrease in postoperative UCLA score (0.0
compared with 1.0; p < 0.001) was noted for BHR compared with
total hip arthroplasty, whichwas clinically important according to
the MCID of 0.92. Furthermore, use of the BHR provided a
greater likelihood of remaining highly active compared with total
hip arthroplasty (61% versus 20%; p < 0.001). The failure rate in
the total hip arthroplasty group was similar to that in the BHR
matched cohort, with 3 revisions at an average of 4.8 years (1.5 to
7.0 years) due to infection, to femoral component failure, and to
taper corrosion. Results are summarized in Table VI.
Discussion
Although several international series have reported excel-lent results for various surface replacement arthroplasty
designs25-27, we are the ﬁrst, to our knowledge, to describe the
intermediate-to-long-term BHR results from a U.S. series. In 324
hips with an average follow-up of 7.2 years, we demonstrated an
estimated rate of survival of 97.2% and 93.8% at 5 and 10 years,
respectively. Furthermore, in patients ﬁtting our institution’s
current inclusion criteria, the survival rate was 98.1% and 96.8%
at 5 and 10 years, respectively. BHR patients showed signiﬁcant
improvements in mHHS and UCLA activity scores, with post-
operative scores comparing favorably to those of the designing-
surgeon series12. Additionally, 98.4% of the patients were satisﬁed
with their BHR. These ﬁndings corroborate the excellent clinical
outcomes and survivorship demonstrated in international trials
and short-term studies from within the U.S.8,14,17,28.
When matched on the basis of preoperative UCLA score,
diagnosis, age, sex, and BMI, the BHR patients demonstrated
signiﬁcant improvements in the postoperative UCLA score
compared with those undergoing total hip arthroplasty. More
importantly, when assessing the highly active subset of patients
with preoperative UCLA scores of 9 to 10 (participation in
impact sports), the BHR patients demonstrated both statisti-
cally signiﬁcant and clinically important advantages compared
with total hip arthroplasty according to the MCID for the
UCLA established by SooHoo et al. (0.92)23. Despite similar
preoperative activity levels, this subset of BHR patients was
41%more likely to participate in impact sports postoperatively.
These results may suggest that, even when matched by pre-
operative activity level and relevant demographic factors, BHR
patients attain greater levels of activity after surgery. Such
ﬁndings may support an indication for the use of BHR in highly
active patients who wish to remain active after hip arthroplasty.
These results corroborate the ﬁndings of previous studies de-
scribing advantages for surface replacement arthroplasty with
respect to postoperative activity and return to sport6,29.
It is important to note, however, that patients most often
self-select for BHR procedures. Observed differences in the
postoperative UCLA score, therefore, may be due to a higher
degree of patient motivation resulting from this selection bias.
Furthermore, surgeon-imposed limitations may contribute to
these differences. While we routinely allow unrestricted activity
in BHR patients at 6 months postoperatively, many arthroplasty
surgeons recommend against high-impact sports following total
hip arthroplasty30. A consensus survey of arthroplasty surgeons,
for example, recommended against participation in racquetball/
squash, jogging, contact sports, baseball/softball, and high-impact
aerobics following total hip arthroplasty31.
We report 14 revisions. Two cases underwent revision at
an outside hospital for continued idiopathic pain. Neither of
these patients had evidence of bone-on-bone osteoarthritis on
preoperative radiographs, which may be a risk factor for dis-
satisfaction following hip arthroplasty32. One of the 2 patients
demonstrated no improvement following conversion to total
hip arthroplasty and had the lowest UCLA and mHHS values
among all revision BHR patients in our cohort. The other
patient with unexplained pain who underwent revision at an
outside institution has since been lost to follow-up.
Eight (73%) of the 11 aseptic revisions had smaller
components, with a femoral head size of <50 mm. This mirrors
other reports of increased complication and failure rates among
patients with a component head size of <50 mm17,33. Of the 3
aseptic revisions with larger head sizes, 1 patient had a cyst that
was grafted intraoperatively and subsequently experienced fem-
oral component loosening requiring revision at 5.7 years (Fig. 5).
Two of 5 cases with grafting of cysts (1 osteonecrotic, 1 arthritic
cyst) went on to femoral failure. Another patient with persistent
pain postoperatively (head size of 54 mm) was revised at 6 weeks.
Although radiographs did not demonstrate clear technical issues,
1885
THE JOURNAL OF BONE & JOINT SURGERY d J B J S .ORG
VOLUME 100-A d NUMBER 21 d NOVEMBER 7, 2018
FIVE TO TEN-YEAR RESULTS OF THE BIRMINGHAM HIP RESURFAC ING
IMPLANT IN THE U.S.
incomplete seating/impaction of the implant may have contrib-
uted to the early revision.
This study had many limitations. First, it was performed
retrospectively and involved multiple surgeons. While the ideal
study would randomize surgical candidates to BHR or total hip
arthroplasty to allow for comparison, Haddad et al. demon-
strated difﬁculty enrolling study patients in a prospective ran-
domized trial comparing BHR and total hip arthroplasty due
to many patients speciﬁcally seeking out surface replacement
arthroplasty6.
In conclusion, the current study demonstrated excellent
survivorship and clinical outcomes at 5 to 10-year follow-up
for BHR procedures performed at a single center in the U.S. In
patients representing the current BHR inclusion criteria at this
center, implant survival was extremely high, with nearly all
patients attaining their goal of remaining extremely active,
signiﬁcantly more often than a matched cohort of standard
total hip arthroplasty patients. These results are at intermediate
term, however (5 to 10 years), and further follow-up is nec-
essary to ensure the safety and efﬁcacy in this young, active
Fig. 5
Figs. 5-A through 5-E A patient with a cyst grafted intraoperatively who underwent revision for femoral component loosening at 5.7 years following the BHR
procedure.Fig. 5-A Preoperative anteroposterior radiograph demonstrating cystic change in the femoral head. Fig. 5-B Intraoperative image demonstrating
a large cyst of the femoral head. Fig. 5-C Postoperative anteroposterior radiograph demonstrating a well-aligned, well-ﬁxed BHR implant. Fig. 5-D The
patient did well for 5.7 years, then experienced the onset of groin pain, with postoperative anteroposterior radiographs demonstrating femoral component
loosening prior to conversion to total hip arthroplasty.Fig. 5-EPostoperative anteroposterior radiograph demonstratingwell-aligned,well-ﬁxed revision total
hip arthroplasty components. Revisionwasstraightforward,with theBHRshell retainedand the cementlessstemcombinedwith adualmobility articulation.
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patient population. In addition, with the numerous reports
of complications of MoM surface replacement and the over-
all higher revision rate of surface replacement arthroplasty
versus total hip arthroplasty in registry reports3, careful patient
selection must be emphasized. Finally, because complication
rates with surface replacement arthroplasty are nearly 4 times
lower among high-volume hip specialists compared with lower-
volume surgeons10, results of the current study may not be
generalizable to lower-volume surgeons. n
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